Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 17 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
LONDON PHARMA from Elsene, company number BE0459894717, closed financial year 2025 with a result of € 13,884 after tax. For that financial year LONDON PHARMA recorded a gross margin of € 95,778 and equity of € 68,924. Compared with financial year 2024, the result moved from € 700 to € 13,884. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 68,924
▲ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 13,884
▲ € 13,184 vs 2024
Profit after tax over the fiscal year.
€ 13,959
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 50,332.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 55,720
▼ 20% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 13,150
▼ 33% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 73,887
▲ 23% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,123
▲ 29% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 95,834 | € 99,311 | € 91,435 | € 95,778 | ▲ 5% |
| Profit after taxes | € 23,132 | € 13,552 | € 700 | € 13,884 | ▲ € 13,184 |
| Equity | € 40,789 | € 54,340 | € 55,040 | € 68,924 | ▲ 25% |
| Total debts | € 85,160 | € 101,224 | € 93,677 | € 92,127 | ▼ 2% |
| Cash | € 28,592 | € 5,364 | - | € 13,959 | |
| Retained profit | € 22,196 | € 35,748 | € 36,448 | € 50,332 | ▲ 38% |
| Bank debt | € 0 | € 0 | € 4,313 | € 0 | ▼ 100% |
| Balance sheet total | € 125,949 | € 155,564 | € 148,717 | € 161,051 | ▲ 8% |
Key figures of LONDON PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LONDON PHARMA?
What happened at LONDON PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 13,884 (▲ € 13,184 vs 2024). Source: NBB ↗
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
- Georg Ingels became a director. NBB
In short
From € 23,132 profit in 2022 to € 13,884 profit in 2025.
Paid € 6,384 in corporate taxes since 2022.
Best year ever: 2022, with € 23,132 profit.
A new publication or filing at LONDON PHARMA? We notify you, reason included.
Follow LONDON PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind LONDON PHARMA is Georg Ingels. Georg Ingels is also behind BERGIES.
Directors
According to the 2025 annual accounts
since 1997
Establishments
Establishment units
Physical locations of this company
Troonstraat 57
1050 Elsene
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0459.894.717
- VAT number
- BE 0459.894.717
- Registered office
- Troonstraat 57, 1050 Elsene
- Names & denominations
- LONDON PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 January 1997
- Peppol
- Active · Active since 13 Oct 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers